Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qualigen Therapeutics, Inc.

3.26
-0.0560-1.69%
Post-market: 3.360.0954+2.92%18:25 EDT
Volume:9.76K
Turnover:32.24K
Market Cap:5.34M
PE:-0.08
High:3.40
Open:3.40
Low:3.26
Close:3.32
Loading ...

Company Profile

Company Name:
Qualigen Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
4
Office Location:
5857 Owens Avenue,Suite 300,Carlsbad,California,United States
Zip Code:
92008
Fax:
- -
Introduction:
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Directors

Name
Position
Kevin Richardson II
Interim Chief Executive Officer and Interim Chief Financial Officer and Director
Braeden Lichti
Independent Director
Campbell Becher
President and Director
Cody Price
Independent Director
Graydon Bensler
Independent Director
Robert B. Lim
Independent Director

Shareholders

Name
Position
Kevin Richardson II
Interim Chief Executive Officer and Interim Chief Financial Officer and Director
Campbell Becher
President and Director